Shockwave Medical (NASDAQ:SWAV) shares gained more than 4% on Friday after the company reported its Q4 results, with EPS coming in at $3.71, significantly better than the Street estimate of $1.00.
Revenue was $144 million, compared to the Street estimate of $142.66 million.
The company reiterated its full 2023-year outlook, expecting revenue to be in the range of $660-$680 million, assuming that global staffing issues continue to improve through the year. The Street estimate stands at $658.58 million. The company expects full-year OpEx to be the same percentage of revenue as in 2022 (approximately 61%).